2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial

Publisher： Karger

E-ISSN： 1421-9670|45|1|40-48

ISSN： 0250-8095

Source： American Journal of Nephrology, Vol.45, Iss.1, 2016-11, pp. : 40-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized Trial of Methylcobalamin and Folate Effects on Homocysteine in Hemodialysis Patients

By  

Nephron, Vol. 91, Iss. 1, 2002-05 ,pp. : 58-63

Karger

Access to resources Recommend Favorite

Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics

By  

Kidney and Blood Pressure Research, Vol. 27, Iss. 4, 2004-09 ,pp. : 259-266

Karger

Access to resources Recommend Favorite

Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients Under Maintenance Hemodialysis

By  

Blood Purification, Vol. 40, Iss. 2, 2015-07 ,pp. : 127-132

Karger

Access to resources Recommend Favorite

Use of 2MD, a Novel Oral Calcitriol Analog, in Hemodialysis Patients with Secondary Hyperparathyroidism

By  

American Journal of Nephrology, Vol. 43, Iss. 3, 2016-04 ,pp. : 213-220

Karger

Access to resources Recommend Favorite

Effects of Dialysate Glucose Concentration on Heart Rate Variability in Chronic Hemodialysis Patients: Results of a Prospective Randomized Trial

By  

Kidney and Blood Pressure Research, Vol. 34, Iss. 5, 2011-05 ,pp. : 334-343

Karger

Access to resources Recommend Favorite